Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism

European Journal of Clinical Pharmacology

Volumn 66, Issue 7, 2010, Pages 697-703

  Djordjevic, Natasa ^a,b   Ghotbi, Roza ^a   Jankovic, Slobodan ^b   Aklillu, Eleni ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Coffee; CYP1A2; Induction; Polymorphisms

Indexed keywords

ADENINE; CYTOCHROME P450 1A2; CYTOSINE; GUANINE; PARAXANTHINE; THYMINE; COFFEE; CYP1A2 PROTEIN, HUMAN;

ARTICLE; CIGARETTE SMOKING; COFFEE; CONTROLLED STUDY; DELETION MUTANT; DRINKING BEHAVIOR; ENZYME ACTIVITY; FEMALE; FOOD INTAKE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN INDUCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SERBIA; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; VOLUNTEER; BIOSYNTHESIS; CAUCASIAN; COMPARATIVE STUDY; DRUG EFFECTS; ENZYME INDUCTION; GENETIC POLYMORPHISM; GENETICS;

COFFEE; CYTOCHROME P-450 CYP1A2; ENZYME INDUCTION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; SERBIA; SWEDEN;

EID: 77955585752     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0823-4     Document Type: Article

References (29)

1. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T (1994) Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 3:413-421
2. Zhou SF, Wang B, Yang LP, Liu JP (2010) Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev (in press)
3. Bageman E, Ingvar C, Rose C, Jernstrom H (2008) Coffee consumption and CYP1A2*1F genotype modify age at breast cancer diagnosis and estrogen receptor status. Cancer Epidemiol Biomarkers Prev 17:895-901
4. Palatini P, Ceolotto G, Ragazzo F, Dorigatti F, Saladini F, Papparella I, Mos L, Zanata G, Santonastaso M (2009) CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens 27:1594-1601
5. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, Ingelman-Sundberg M (2003) Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with singlenucleotide polymorphisms in intron 1. Mol Pharmacol 64:659-669
6. Kashuba AD, Bertino JS Jr, Kearns GL, Leeder JS, James AW, Gotschall R, Nafziger AN (1998) Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther 63:540-551
7. Sachse C, Brockmoller J, Bauer S, Roots I (1999) Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449
8. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T (1999) Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 125:803-808
9. Djordjevic N, Ghotbi R, Bertilsson L, Jankovic S, Aklillu E (2008) Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol 64:381-385
10. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L (2007) Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 63:537-546
11. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T (1999) Detection of three genetic polymorphisms in the 5′- flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 90:899-902
12. Han XM, Ouyang DS, Chen XP, Shu Y, Jiang CH, Tan ZR, Zhou HH (2002) Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br J Clin Pharmacol 54:540-543
13. Parker AC, Pritchard P, Preston T, Choonara I (1998) Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol 45:176-178.
14. Fuhr U, Anders EM, Mahr G, Sorgel F, Staib AH (1992) Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 36:942-948
15. Gunes A, Ozbey G, Vural EH, Uluoglu C, Scordo MG, Zengil H, Dahl ML (2009) Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 10:769-778
16. Djordjevic N, Carrillo JA, Gervasini G, Jankovic S, Aklillu E (2010) In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. Eur J Clin Pharmacol (in press)
17. Lindroos K, Sigurdsson S, Johansson K, Ronnblom L, Syvanen AC (2002) Multiplex SNP genotyping in pooled DNA samples by a four-colour microarray system. Nucleic Acids Res 30:e70
18. Chevalier D, Cauffiez C, Allorge D, Lo-Guidice JM, Lhermitte M, Lafitte JJ, Broly F (2001) Five novel natural allelic variants- 951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)-of the human CYP1A2 gene in a French Caucasian population. Hum Mutat 17:355-356
19. Kootstra-Ros JE, Smallegoor W, van der Weide J (2005) The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann Clin Biochem 42:216-219
20. Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, Garner RC, Boobis AR, Wolf CR, Gooderham NJ (2003) Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 55:68-76
21. Pavanello S, Pulliero A, Lupi S, Gregorio P, Clonfero E (2005) Influence of the genetic polymorphism in the 5′-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. Mutat Res 587:59-66
22. Shimoda K, Someya T, Morita S, Hirokane G, Yokono A, Takahashi S, Okawa M (2002) Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5′- flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 26:261-265
23. Nordmark A, Lundgren S, Ask B, Granath F, Rane A (2002) The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women. Br J Clin Pharmacol 54:504-510
24. Takata K, Saruwatari J, Nakada N, Nakagawa M, Fukuda K, Tanaka F, Takenaka S, Mihara S, Marubayashi T, Nakagawa K (2006) Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy. Eur J Clin Pharmacol 62:23-28
25. Krul C, Hageman G (1998) Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 709:27-34
26. Fuhr U, Jetter A, Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther 81:270-283
27. Fuhr U, Rost KL (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 4:109-116
28. Kalow W, Tang BK (1991) Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49:44-48
29. Abernethy DR, Todd EL (1985) Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 28:425-428